Cargando…
Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510
Autores principales: | Wind, Selinde S., Jansen, Manon A. A., Rijsbergen, Melanie, van Esdonk, Michiel J., Ziagkos, Dimitrios, Cheng, Wing C., Niemeyer-van der Kolk, Tessa, Korsten, John, Gruszka, Agnieszka, Schmitz-Rohmer, Debora, Bonnel, David, Legouffe, Raphael, Barré, Florian, Bekkenk, Marcel W., de Haas, Ellen R. M., Quint, Koen D., Schnidar, Harald, Rolli, Melanie, Streefkerk, Henk Johan, Burggraaf, Jacobus, Vermeer, Maarten H., Rissmann, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001047/ https://www.ncbi.nlm.nih.gov/pubmed/36900424 http://dx.doi.org/10.3390/cancers15051485 |
Ejemplares similares
-
Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial
por: Wind, Selinde S., et al.
Publicado: (2022) -
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
por: Johnson, Faye M, et al.
Publicado: (2022) -
Cryogenics: 15.10.Solenoid
Publicado: (2004) -
Cryogenics: 15.10.Solenoid
Publicado: (2005) -
Cryogenics: 15.10.Solenoid
Publicado: (2005)